Trivitron Healthcare has announced its strategic partnership with Diasorin Group, a global leader in USD 11 billion immune segment to enter immunodiagnostic market in India.

Having already made its mark as a largest player in Indian IVD division, the pact with Diasorin will complete Trivitron’s offerings in the IVD product market by entering high growth immunodiagnostics market.

The new entity DiaSorin- Trivitron Healthcare Private Limited, will see stakes of 51 per cent and 49 per cent respectively.  The company will directly operate in the Indian diagnostics market thus placing Trivitron as a leader in immunodiagnostic market over the next 3 years.

Dr G S K Velu, founder and MD of Trivitron Group of Companies said that the joint venture with Diasorin is an important milestone. We are confident that it  will provide unique positioning in Immunoassay segment with the most innovative and extensive Immunoassay platform using CLIA/ELISA/ RIA/MDx.

The Indian healthcare scenario has undergone a radical change with a shift from community acquired diseases to lifestyle diseases. Noting this change, in the forthcoming years, immunodiagnostic and infectious disease testing will be one of the key growth drivers for the IVD market.

With more than 25 years of expertise in the immunodiagnostic space brought in by Dr Velu, this partnership will only strengthen Trivitron’s immunodiagnostic offerings. His association with global players like Siemens and DPC for RIA with Lab Systems and Adaltis for the ELISA range will enable Trivitron Diasorin venture to gain the leadership position in the IVD segment.

Trivitron has been a contributor in this segment wherein the company installed immunoassay analyzersin almost 70 per cent of labs in India. It is the first company to launch the CLIA (Chemi Luminescence Immuno Assay) platform in India.

The  JV agreement with Trivitron is really important for our  success in such relevant market as India, and represents an important pillar of the current and future expansion strategy of DiaSorin Group in Asia Pacific, said Carlo Rosa, CEO of DiaSorin Group

Trivitron was established in the year 1997 to produce a range of imaging diagnostics products including Ultrasound and Color Doppler machines, X Ray equipments, image enhancement solutions and radiation protection apparels, cardiac diagnostics instruments, an entire range of operating room solutions, and in-vitro diagnostics (IVD) instruments and  reagents.

The DiaSorin Group has been an international player in the market for in vitro diagnostics, a specific segment of immunodiagnostics that encompasses the categories of immunochemistry and infectious immunology.